 |
lentiviral transfected chimeric antigen receptor T-cells modified to target B-cell maturation antigen and CS1 |
|---|---|
| Trade Name | |
| Orphan Indication | Multiple myeloma |
| USA Market Approval | USA |
| USA Designation Date | 2017-12-14 00:00:00 |
| Sponsor | iCell Gene Therapeutics;25 Health Sciences Drive, Suite 118;Stony Brook, New York, 11793 |
Related Access Program
AbbVie – Multiple Myeloma
Janssen Research & Development, LLC – Multiple Myeloma
Dana-Farber Cancer Institute – Multiple Myeloma
Bristol-Myers Squibb – Multiple Myeloma
Peking University – Multiple Myeloma
Novartis Pharmaceuticals – Multiple Myeloma
Onyx Pharmaceuticals, Inc., an Amgen subsidiary – Multiple myeloma